Sugi Predict

Sugi Predict / Compounds / SCHEMBL19252451

SCHEMBL19252451

SCHEMBL19252451

O=[N+]([O-])c1ccnc2c1cc(I)n2CC(F)(F)F

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.33
▸ KDM4E B2RXH2 6/20 0.33
▸ MAPT P10636 6/20 0.33
▸ METAP2 P50579 6/20 0.33
▸ MEN1 O00255 6/20 0.33
▸ KMT2A Q03164 6/20 0.33
▸ LMNA P02545 5/20 0.33
▸ TDP1 Q9NUW8 4/20 0.33
▸ HTT P42858 4/20 0.33
▸ PKM P14618 3/20 0.33
▸ SMN1; SMN2 Q16637 3/20 0.33
▸ IDO1 P14902 2/20 0.33
▸ TDO2 P48775 2/20 0.33
▸ CASP6 P55212 2/20 0.33
▸ CTSB P07858 2/20 0.33
▸ POLB P06746 2/20 0.33
▸ L3MBTL1 Q9Y468 2/20 0.33
▸ HSP90AA1 P07900 2/20 0.33
▸ OPRK1 P41145 2/20 0.33
▸ THRB P10828 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29876445 0.76 CCR2 (0.41) ALDH1A1MAPTMEN1KMT2ALMNA
SCHEMBL19252141 0.76 CCR2 (0.41) ALDH1A1MAPTMEN1KMT2ALMNA
SCHEMBL26380619 0.68 MAPT (0.36) ALDH1A1KDM4EMAPTMETAP2MEN1
SCHEMBL23144709 0.67 CCR2 (0.40) ALDH1A1MAPTMEN1KMT2ALMNA
SCHEMBL26378306 0.67 CCR2 (0.40) ALDH1A1MAPTMEN1KMT2ALMNA
SCHEMBL29812153 0.67 CCR2 (0.40) ALDH1A1MAPTMEN1KMT2ALMNA
SCHEMBL23144169 0.65 ALDH1A1 (0.38) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL12146923 0.61 MAPT (0.40) ALDH1A1KDM4EMAPTMETAP2MEN1
SCHEMBL2887417 0.61 GAA (0.50) ALDH1A1KDM4EMAPTMETAP2MEN1
SCHEMBL31363399 0.60 HTR6 (0.36) CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220213062-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2022-07-07 — — US disclosed
US-11339141-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2022-05-24 — — US disclosed
US-20210002252-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2021-01-07 — — US disclosed
US-10640485-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2020-05-05 — — US disclosed
US-20190119249-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2019-04-25 — — US disclosed
EP-3416638-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV Pharmaceuticals, Inc. (US) 2018-12-26 — — EP disclosed
CN-109069481-A Methods and compounds for restoring function of mutant p53 皮姆维制药公司 2018-12-21 — — CN disclosed
US-10138219-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS (US) 2018-11-27 — — US disclosed
WO-2017143291-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. (US) 2017-08-24 — — WO disclosed
US-20170240525-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2017-08-24 — — US disclosed
US-20170240525-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2017-08-24 — — US disclosed
WO-2017143291-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. (US) 2017-08-24 — — WO disclosed
US-20170240525-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2017-08-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170240525-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, KRAS ALDH1A1 1538/4885KDM4E 2994/4885MAPT 4269/4885
US-11339141-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, KRAS ALDH1A1 1538/4885KDM4E 2994/4885MAPT 4269/4885
US-20220213062-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, KRAS ALDH1A1 1538/4885KDM4E 2994/4885MAPT 4269/4885
US-20190119249-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, KRAS ALDH1A1 1538/4885KDM4E 2994/4885MAPT 4269/4885
US-10640485-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, KRAS ALDH1A1 1538/4885KDM4E 2994/4885MAPT 4269/4885
US-20210002252-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, KRAS ALDH1A1 1538/4885KDM4E 2994/4885MAPT 4269/4885
US-10138219-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, KRAS ALDH1A1 1538/4885KDM4E 2994/4885MAPT 4269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.